Purchase of shares by Chief Financial Officer

Sinclair Pharma plc

Purchase of shares by Chief Financial Officer

24 May 2016, Sinclair Pharma plc (SPH.L) ("Sinclair" or the "Company") the international aesthetics company, was advised on 23 May, that on that day Alan Olby, Chief Financial Officer, acquired 50,000 ordinary shares of 1p each ("Ordinary Shares") in the Company at 35.5p per Ordinary Share. Alan Olby is not on the Board of Sinclair but he will be deemed a PDMR under the Market Abuse Regulation which comes into force in July 2016.

Following these purchases, Mr Olby is interested in 173,090 Ordinary Shares, 0.04% of the issued share capital of the Company.

For further information please contact:

Sinclair Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

Notes to Editors:

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.

For more information, please visit www.sinclairpharma.com